Health TrialsbyHealthPanel

Feasibility of Modulating Cognitive Control in OCD

ConditionObsessive-Compulsive Disorder (OCD)
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorDartmouth-Hitchcock Medical Center

About this trial

This study tests out procedures to look at whether a type of brain stimulation called transcranial magnetic stimulation impacts flexible shifts in behavior in obsessive-compulsive disorder (OCD). This study examines whether study procedures are feasible and acceptable to people participating in the study, but does not determine whether this type of brain stimulation causes changes.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Current primary DSM-5 OCD diagnosis and current Y-BOCS total score of ≥16 (OCD group, only) or no current diagnosis of an emotional disorder, and no known history of OCD, PTSD, anxiety disorder(s), or recurrent major depressive disorder (Healthy participant group, only)

18-60 years of age

ability to speak, read, write, and understand English sufficiently well to complete study procedures and provide informed consent

psychotherapy and/or psychiatric medication use remain stable for 6 weeks prior to study entry

Disqualifiers

Presence of current psychiatric diagnosis (healthy control group, only)

active substance use disorder

history of mania or hypomania, or lifetime presence of significant psychotic symptoms

active suicidal or homicidal ideation

Trial design

Design model

Parallel

Treatments tested in this trial

  • continuous theta-burst transcranial magnetic stimulation (cTBS)

    Device

    3 consecutive daily sessions of cTBS

Treatment groups

12 Participants
are divided into 2 treatment groups
Group A: Obsessive-compulsive disorder (OCD)Other 1 intervention
Group B: Healthy Adult ParticipantsOther 1 intervention

Trial outcomes

Primary outcomes

1

Rate of enrollment

Percent of screened participants who are determined to be eligible and enrolled.

Time frame
At study enrollment

Secondary outcomes

1

Rates of visit completion

Percent (%) of enrolled participants completing each study visit

Time frame
From enrollment to date of post-TMS study visit (approximately 1 week)
2

Peak cTBS intensity tolerated

Average of peak intensity (up to target intensity) tolerated during cTBS sessions

Time frame
From enrollment to end of TMS sessions (approximately 1 week)

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Dartmouth-Hitchcock Medical Center

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: